Peregrine Ventures has already closed $101 million of the planned $300 million fund, with participation from leading Israeli investors.

Eyal Lifschitz, managing partner at Peregrine, says there is huge demand and opportunity in medical technologies in Israel and 'foreign investors recognize this.'